Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

J. Baselga; I. Bradbury; H. Eidtmann

doi:10.1016/S0140-6736(12)60268-2

Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

J. Baselga, I. Bradbury, H. Eidtmann

Business, Management and Accounting

科研成果: 期刊稿件 › 评论/辩论 › 同行评审

5 引用（Scopus）

源语言	英语
页（从-至）	616
页数	1
期刊	The Lancet
卷	379
期	9816
DOI	https://doi.org/10.1016/S0140-6736(12)60268-2
出版状态	已出版 - 2月 2012

!!!ASJC Scopus Subject Areas

一般医学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1016/S0140-6736(12)60268-2

其它文件与链接

引用此

@article{257091b308de445f94a6c6a2f16fb571,

title = "Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))",

author = "J. Baselga and I. Bradbury and H. Eidtmann",

year = "2012",

month = feb,

doi = "10.1016/S0140-6736(12)60268-2",

language = "English",

volume = "379",

pages = "616",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9816",

}

TY - JOUR

T1 - Erratum

T2 - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

AU - Baselga, J.

AU - Bradbury, I.

AU - Eidtmann, H.

PY - 2012/2

Y1 - 2012/2

UR - http://www.scopus.com/inward/record.url?scp=84857211691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857211691&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(12)60268-2

DO - 10.1016/S0140-6736(12)60268-2

M3 - Comment/debate

AN - SCOPUS:84857211691

SN - 0140-6736

VL - 379

SP - 616

JO - The Lancet

JF - The Lancet

IS - 9816

ER -